# Single-site, Open-label, Randomized, Cross-over Study in Healthy Chinese Subjects to Evaluate the Bioequivalence of Single-dose Rotigotine Transdermal Patch Comparing 2 Different Formulations

> **NCT02070796** · PHASE1 · COMPLETED · sponsor: **UCB Pharma SA** · enrollment: 50 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Rotigotine PR2.2.1
- **DRUG:** Rotigotine PR2.1.1

## Key facts

- **NCT ID:** NCT02070796
- **Lead sponsor:** UCB Pharma SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2014-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02070796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02070796, "Single-site, Open-label, Randomized, Cross-over Study in Healthy Chinese Subjects to Evaluate the Bioequivalence of Single-dose Rotigotine Transdermal Patch Comparing 2 Different Formulations". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02070796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*